MRTX — Mirati Therapeutics Share News
0.000.00%
Last trade - 00:00- $4.12bn
- $3.15bn
- $12.44m
Tango Therapeutics surges after Guggenheim raises PT on upbeat rival drug data
Mirati surges after upsized equity raise, CEO departure, lung cancer drug update
Brief: Mirati Therapeutics Announces Pricing Of Upsized Public Offering of 9.67 Mln Shares At A Price To Public Of $27.80 Per Share
Mirati Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Mirati Therapeutics Announces Departure Of Chief Executive Officer David Meek
Brief: Mirati Therapeutics Q2 product revenue USD 13.365 million
Mirati Therapeutics Inc expected to post a loss of $3.17 a share - Earnings Preview
British billionaire Joe Lewis pleads not guilty to US insider trading charges (updated)
British billionaire Joe Lewis pleads not guilty to US insider trading charges (updated)
British billionaire Joe Lewis pleads not guilty to US insider trading charges (updated)
British billionaire Joe Lewis to appear in US court on insider trading charges (updated)
US SEC charges British billionaire Joe Lewis with insider trading
US charges British billionaire Joe Lewis with insider trading (updated)
U.S. STOCKS ON THE MOVE-PPG Industries, Thorne HealthTech, Energy firms
U.S. STOCKS ON THE MOVE-Intuitive Surgical, Carvana, Roper
Mirati Therapeutics falls as EU regulator declines to back cancer drug
U.S. STOCKS ON THE MOVE-Comerica, American Express, Harley-Davidson
Mirati Therapeutics falls as EU regulator declines to back cancer drug
EU regulator declines to back Mirati's lung cancer drug (updated)